Screener
Arcutis Biotherapeutics, Inc. ARQT Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
FAQ
- What is Arcutis Biotherapeutics, Inc.'s total equity?
- Arcutis Biotherapeutics, Inc. (ARQT) reported total equity of $220.58M in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s total equity changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s total equity increased by 58.7% year-over-year, from $138.97M to $220.58M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s total equity?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s total equity has grown at a -6.9% compound annual growth rate (CAGR), from $270.62M to $189.48M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Arcutis Biotherapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude